FDA approves Neurocrine’s Ingrezza to treat tardive dyskinesia

This article was originally published here

Neurocrine Biosciences has secured approval from the US Food and Drug Administration (FDA) for its Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia (TD).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply